I’ve written quite a few times about
mavrilimumab on this blog. The blogpost on “Mavrilimumab at the EULAR 2012” [1]
attracted about 9000 visitors. And I’ve also written about mavrilimumab in
Chinese [2]. So I might say that I’m interested in mavrilimumab.
Mavrilimumab is a human
granulocyte-macrophage colony-stimulating factor receptor-α (GM–CSFR-α)
monoclonal antibody. At the 2017 EULAR Annual Meeting we’ve only seen one
study.
G. Burmester and colleagues presented [3]: “RESULTS
OF A LONGITUDINAL REVIEW OF PULMONARY FUNCTION AND SAFETY DATA IN A PHASE IIB
CLINICAL PROGRAMME TESTING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
(GM–CSF) RECEPTOR ANTAGONIST MAVRILIMUMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS
(RA)”. The authors concluded: “We believe this is the most comprehensive
longitudinal study of pulmonary function in a clinical RA programme.” O.K., but
other seems to do fine without the need to such testing. And after 5 long years
we’re still in phase 2b. The authors also concluded: “… its acceptable safety
profile advocates initiation of Phase III studies with mavrilimumab. Further
studies are now required to fully characterise pulmonary function over time in
RA.” Further studies on pulmonary function!
My opinion in 2012: “this doesn't seem to be
the start of a success story”. Clinical Trials lists 6 studies on mavrilimumab,
which are completed or have been terminated [4]. In German we have the word “dümpeln”,
which means “to bob up and down” or “to stagnate”. Mavrilimumab dümpels. But
maybe the sponsor will initiate a phase 3 study.
Links and
References:
[3] Annals of the Rheumatic Diseases, volume
76, supplement 2, year 2017, page 564 / Session: Rheumatoid arthritis - other
biologic treatment , (Poster Presentations ) / DOI:
10.1136/annrheumdis-2017-eular.3131
.
No comments:
Post a Comment